In October 2024, the Department for Promotion of Industry and Internal Trade (DPIIT) expanded the Production-Linked Incentive (PLI) scheme for pharmaceuticals, extending eligibility to Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs)—a significant shift aimed at reducing India's import dependency and boosting domestic manufacturing capacity.
For mid-sized manufacturers and bulk-drug producers, this creates fresh incentive opportunities but imposes strict compliance, capex documentation, and production-target registration deadlines rolling through December 2024 and into Q1 2025.
Market signals
PLI 2.0 requires manufacturers to declare capex commitments and baseline production data to the Ministry by defined quarterly milestones. Missing or late filings trigger disqualification; many SMEs lack integrated ERP systems to track and validate these figures in real time.
Scheme incentives hinge on demonstrable domestic sourcing ratios and third-party lab certifications (BIS, NABL accreditation) for APIs. Firms must pre-audit supply chains and secure testing slots—a 6–8 week turnaround in many cases—before claiming production eligibility.
PLI incentive claims interact with GST input-credit rules and FEMA foreign-investment restrictions if capex is financed externally. Incorrect classification or advance reporting can delay payouts by 3–6 months and trigger audit notices from CBIC and RBI.
PLI 2.0 is a genuine growth lever for India's API sector, but the compliance architecture is rigorous: manufacturers must register production units, file capex schedules, obtain NABL-accredited test reports, and maintain auditable GST and FEMA records in lockstep. Vinayakam Consultants supports pharma clients through PLI eligibility audits, regulatory alignment with DPIIT and DGFT guidelines, ERP readiness for production tracking, and coordinated GST-FEMA structuring to protect incentive realization and avoid post-claim disqualifications.
Your action checklist
- Audit existing capex records and production data against DPIIT's December 2024 baseline-filing template; engage a cost accountant if figures are unreconciled.
- Identify and pre-register all APIs and KSMs to be manufactured; source NABL-accredited testing partners and map 6–8 week lead times before Q1 2025 claims.
- Review GST input-credit eligibility on capex and raw materials; confirm FEMA compliance for any foreign debt or equity financing tied to PLI-funded projects.
- Establish a compliance calendar: mark DPIIT filing windows, auditor nomination deadlines, and production-reporting cycles; assign an internal compliance owner and brief your CFO on linkages to statutory audit and board disclosures.